Allogene Therapeutics, Inc. Lease, Cost
Allogene Therapeutics, Inc. (ALLO) reported Lease, Cost of $3.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-12
- Allogene Therapeutics, Inc. lease, cost for the quarter ending 2026-06-30 was $3.10M, a 3.65% increase year-over-year.
- Allogene Therapeutics, Inc. lease, cost for the quarter ending 2026-03-31 was $2.94M, a 4.41% decline year-over-year.
- Allogene Therapeutics, Inc. lease, cost for the quarter ending 2025-12-31 was $3.14M, a 8.62% decline year-over-year.
- Allogene Therapeutics, Inc. lease, cost for the quarter ending 2025-09-30 was $3.07M, a 17.70% decline year-over-year.
- Allogene Therapeutics, Inc. lease, cost for fiscal 2025 was $12.28M, a 15.73% decline from fiscal 2024.
- Allogene Therapeutics, Inc. lease, cost for fiscal 2024 was $14.57M, a 7.84% decline from fiscal 2023.
- Allogene Therapeutics, Inc. lease, cost for fiscal 2023 was $15.81M, a 14.56% increase from fiscal 2022.
- Allogene Therapeutics, Inc. lease, cost for fiscal 2022 was $13.80M, a 50.98% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 3 month as first filed | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month | Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3.10M 10-Q · filed 2026-08-12 | $6.04M 10-Q · filed 2026-08-12 | $9.18M derived: sum of 3 quarters · filed 2026-08-12 | $12.25M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | $2.94M 10-Q · filed 2026-05-13 | $6.08M derived: sum of 2 quarters · filed 2026-05-13 | $9.15M derived: sum of 3 quarters · filed 2026-05-13 | $12.14M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.21M derived: sum of 2 quarters · filed 2026-03-12 | $9.20M derived: sum of 3 quarters · filed 2026-08-12 | $12.28M 10-K · filed 2026-03-12 | ||
| 2025-09-30 | $3.07M 10-Q · filed 2025-11-06 | $6.06M derived: sum of 2 quarters · filed 2026-08-12 | $9.14M 10-Q · filed 2025-11-06 | $12.58M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $2.99M 10-Q · filed 2026-08-12 | $2.99M 10-Q · filed 2025-08-13 | $6.07M 10-Q · filed 2026-08-12 | $9.50M derived: sum of 3 quarters · filed 2026-08-12 | $13.24M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $3.08M 10-Q · filed 2026-05-13 | $6.51M derived: sum of 2 quarters · filed 2026-05-13 | $10.25M derived: sum of 3 quarters · filed 2026-05-13 | $13.77M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $3.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $7.17M derived: sum of 2 quarters · filed 2026-03-12 | $10.69M derived: sum of 3 quarters · filed 2026-03-12 | $14.57M 10-K · filed 2026-03-12 | ||
| 2024-09-30 | $3.73M 10-Q · filed 2025-11-06 | $7.25M derived: sum of 2 quarters · filed 2025-11-06 | $11.14M 10-Q · filed 2025-11-06 | $15.47M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $3.52M 10-Q · filed 2025-08-13 | $7.41M 10-Q · filed 2025-08-13 | $11.73M derived: sum of 3 quarters · filed 2025-08-13 | $15.50M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | $3.89M 10-Q · filed 2025-05-13 | $8.21M derived: sum of 2 quarters · filed 2025-05-13 | $11.98M derived: sum of 3 quarters · filed 2025-05-13 | $15.83M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $8.09M derived: sum of 2 quarters · filed 2025-03-13 | $11.94M derived: sum of 3 quarters · filed 2025-03-13 | $15.81M 10-K · filed 2025-03-13 | ||
| 2023-09-30 | $3.77M 10-Q · filed 2024-11-07 | $7.61M derived: sum of 2 quarters · filed 2024-11-07 | $11.49M 10-Q · filed 2024-11-07 | $15.35M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $3.85M 10-Q · filed 2024-08-07 | $7.72M 10-Q · filed 2024-08-07 | $11.58M derived: sum of 3 quarters · filed 2024-08-07 | $15.37M derived: sum of 4 quarters · filed 2024-08-07 | ||
| 2023-03-31 | $3.87M 10-Q · filed 2024-05-13 | $7.73M derived: sum of 2 quarters · filed 2024-05-13 | $11.52M derived: sum of 3 quarters · filed 2024-05-13 | $15.10M derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $3.86M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $7.65M derived: sum of 2 quarters · filed 2024-03-14 | $11.23M derived: sum of 3 quarters · filed 2024-03-14 | $13.80M 10-K/A · filed 2024-03-14 | ||
| 2022-09-30 | $3.79M 10-Q · filed 2023-11-02 | $7.37M derived: sum of 2 quarters · filed 2023-11-02 | $9.94M 10-Q · filed 2023-11-02 | $12.54M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-06-30 | $3.57M 10-Q · filed 2023-08-02 | $6.15M 10-Q · filed 2023-08-02 | $8.75M derived: sum of 3 quarters · filed 2024-03-14 | $11.05M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-03-31 | $2.58M 10-Q · filed 2023-05-03 | $5.17M derived: sum of 2 quarters · filed 2024-03-14 | $7.47M derived: sum of 3 quarters · filed 2024-03-14 | $9.53M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2021-12-31 | $2.60M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $4.90M derived: sum of 2 quarters · filed 2024-03-14 | $6.95M derived: sum of 3 quarters · filed 2024-03-14 | $9.14M 10-K/A · filed 2024-03-14 | ||
| 2021-09-30 | $2.30M 10-Q · filed 2022-11-02 | $4.36M derived: sum of 2 quarters · filed 2022-11-02 | $6.55M 10-Q · filed 2022-11-02 | $8.81M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2021-06-30 | $2.06M 10-Q · filed 2022-08-09 | $4.25M 10-Q · filed 2022-08-09 | $6.51M derived: sum of 3 quarters · filed 2024-03-14 | $8.71M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2021-03-31 | $2.19M 10-Q · filed 2022-05-04 | $4.46M derived: sum of 2 quarters · filed 2024-03-14 | $6.66M derived: sum of 3 quarters · filed 2024-03-14 | $8.92M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2020-12-31 | $2.27M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $4.47M derived: sum of 2 quarters · filed 2024-03-14 | $6.73M derived: sum of 3 quarters · filed 2024-03-14 | $8.77M 10-K/A · filed 2024-03-14 | $8.77M 10-K · filed 2021-02-25 | |
| 2020-09-30 | $2.20M 10-Q · filed 2021-11-04 | $4.46M derived: sum of 2 quarters · filed 2021-11-04 | $6.50M 10-Q · filed 2021-11-04 | $8.80M derived: sum of 4 quarters · filed 2022-02-23 | ||
| 2020-06-30 | $2.27M 10-Q · filed 2021-08-04 | $4.34M 10-Q · filed 2021-08-04 | $6.60M derived: sum of 3 quarters · filed 2022-02-23 | $8.25M derived: sum of 4 quarters · filed 2022-02-23 | ||
| 2020-03-31 | $2.08M 10-Q · filed 2021-05-05 | $4.33M derived: sum of 2 quarters · filed 2022-02-23 | $5.98M derived: sum of 3 quarters · filed 2022-02-23 | $7.60M derived: sum of 4 quarters · filed 2022-02-23 | ||
| 2019-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $3.91M derived: sum of 2 quarters · filed 2022-02-23 | $5.52M derived: sum of 3 quarters · filed 2022-02-23 | $7.03M 10-K · filed 2022-02-23 | ||
| 2019-09-30 | $1.65M 10-Q · filed 2020-11-04 | $3.27M derived: sum of 2 quarters · filed 2020-11-04 | $4.78M 10-Q · filed 2020-11-04 | |||
| 2019-06-30 | $1.62M 10-Q · filed 2020-08-05 | $3.11M 10-Q · filed 2020-08-05 | ||||
| 2019-03-31 | $1.49M 10-Q · filed 2020-05-06 | |||||
| 2018-12-31 | $1.90M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |